ArticleJCO precision oncology2025
Histologic Subvariants of Retroperitoneal Well-Differentiated Liposarcoma Show Evidence of Clinical and Genomic Progression Toward Dedifferentiated Liposarcoma.
Article in JCO precision oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Tumorigenesis of well-differentiated and dedifferentiated liposarcoma: 12q amplicon architecture, oncogenic cargo, and evolutionary progression.Cancer metastasis reviews · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
purposeSeveral histologic subvariants of retroperitoneal well-differentiated liposarcoma (WDLS) have been described, but their associations with clinical outcomes, underlying genomic differences, and transformation to dedifferentiated liposarcoma (DDLS) are not well-defined.
methodsWe identified 276 patients with primary retroperitoneal WDLS and 353 patients with primary retroperitoneal DDLS who underwent resection between July 1982 and July 2021 at our institution. WDLS histology was reviewed by a sarcoma pathologist and divided into three subvariants: lipoma-like, sclerosing/myxoid, or incipient/early dedifferentiated WDLS. We also performed an exploratory genomic analysis on a subset of 140 patients with available next-generation targeted sequencing data generated using the MSK-IMPACT platform.
resultsCompared with the lipoma-like subvariant, the sclerosing/myxoid (hazard ratio [HR], 3.2) and incipient/early dedifferentiated subvariants (HR, 5.3) and DDLS (HR, 9.6) were independently associated with higher incidence of disease-specific death after controlling for other prognostic factors such as tumor size and resection margins. Both the sclerosing/myxoid (HR, 2.9) and incipient/early dedifferentiated (HR, 5.4) subvariants were also associated with a higher incidence of subsequent dedifferentiation compared with the lipoma-like subvariant. On genomic exploratory analysis, compared with the lipoma-like samples, the sclerosing/myxoid and incipient/early dedifferentiated samples had significantly higher copy number log ratios (CNLRs) of
conclusionWDLS subvariants exhibit both a morphological and genomic progression along the WDLS to DDLS disease spectrum. Distinguishing between them is clinically meaningful for accurate patient counseling and enrollment and stratification in future clinical trials.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.